Refractory Neuroblastoma Active Not Recruiting Phase 2 Trials for Selumetinib (DB11689)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0047201 (Refractory Neuroblastoma) | Active Not Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Treatment |